Harpriya Singh, MD
Gastroenterology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Singh’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A106864 · Current
Licensed to practise in California · since 2009 · expires 2026-10-31 · Punjab University, Dayanand Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$70,544
Medicare paid this office $70,544 for 298 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 120 | $21,264 | $111 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 55 | $12,916 | $235 |
| New patient visit (45+ min) | 83 | $12,093 | $146 |
| Biopsy of large bowel using a flexible endoscope | 77 | $8,992 | $117 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 56 | $4,413 | $77 |
See all 7 services
| Return visit (30+ min) | 120 | $21,264 | $111 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 55 | $12,916 | $235 |
| New patient visit (45+ min) | 83 | $12,093 | $146 |
| Biopsy of large bowel using a flexible endoscope | 77 | $8,992 | $117 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 56 | $4,413 | $77 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 12 | $2,394 | $184 |
| New patient visit (30+ min) | 13 | $1,311 | $101 |
Procedures Medicare counted
| Colonoscopy | 56 | More than 66% of doctors who do this |
| Upper gastrointestinal (GI) endoscopy for acid reflux | 38 | More than 59% of doctors who do this |
Who their Medicare patients are
298 Original Medicare patients in 2024. Average age 73 · Under 65 6% · 85 and older 7% · Women 80% · Also on Medicaid 19% · Health risk score 1.37. At or below the middle of the specialty; the typical gastroenterology clinician is at 1.42.
Conditions among them: High blood pressure 73% · Diabetes 29% · Chronic kidney disease 29% · Cancer 22% · Depression 22% · Coronary heart disease 20% · Atrial fibrillation 18% · COPD 15% · Heart failure 13% · Dementia 6% · Stroke 5%.
The office billed $626,294, Medicare allowed $89,589 and paid $70,544; for 546 services of 17 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 298 | 546 | 73 | 1.37 | $626,294 | $70,544 |
| 2023 | 277 | 523 | 74 | 1.25 | $543,423 | $65,437 |
| 2022 | 254 | 576 | 74 | 1.68 | $523,825 | $59,192 |
| 2021 | 284 | 697 | 73 | 1.43 | $622,304 | $67,141 |
| 2020 | 274 | 718 | 74 | 1.70 | $630,478 | $64,893 |
| 2019 | 325 | 912 | 74 | 1.53 | $733,526 | $80,391 |
| 2018 | 278 | 889 | 74 | 1.57 | $638,529 | $85,455 |
| 2017 | 274 | 907 | 75 | 1.61 | $551,404 | $86,583 |
| 2016 | 251 | 1,078 | 75 | 1.95 | $578,141 | $94,678 |
| 2015 | 266 | 1,143 | 73 | 2.12 | $566,155 | $108,037 |
| 2014 | 266 | 1,040 | 74 | 1.73 | $399,370 | $98,488 |
| 2013 | 263 | 1,034 | 74 | 1.95 | $388,282 | $99,113 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 7 services
| Return visit (30+ min) | 115 | $19,127 | $111 |
| New patient visit (45+ min) | 82 | $11,929 | $145 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 43 | $9,525 | $222 |
| Biopsy of large bowel using a flexible endoscope | 60 | $5,019 | $84 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 53 | $4,131 | $75 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 22 | $2,519 | $114 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 17 | $1,130 | $43 |
2022: 8 services
| Return visit (30+ min) | 110 | $17,908 | $108 |
| New patient visit (45+ min) | 73 | $9,879 | $135 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 39 | $8,183 | $210 |
| Biopsy of large bowel using a flexible endoscope | 64 | $5,562 | $87 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 63 | $5,240 | $79 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 29 | $3,311 | $114 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 31 | $2,772 | $34 |
| New patient visit (30+ min) | 11 | $909 | $83 |
2021: 11 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 63 | $13,739 | $218 |
| Return visit (30+ min) | 51 | $8,226 | $125 |
| Biopsy of large bowel using a flexible endoscope | 86 | $6,558 | $76 |
| New patient visit (45+ min) | 38 | $5,977 | $157 |
| Short return visit (20+ min) | 58 | $4,895 | $74 |
| New patient visit (30+ min) | 53 | $4,628 | $87 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 61 | $4,458 | $72 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 21 | $3,455 | $65 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 26 | $3,441 | $35 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 26 | $3,261 | $125 |
| New patient visit (15+ min) | 12 | $505 | $42 |
2020: 12 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 43 | $9,531 | $222 |
| Short return visit (20+ min) | 95 | $8,813 | $67 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 35 | $7,616 | $65 |
| Biopsy of large bowel using a flexible endoscope | 76 | $7,230 | $95 |
| New patient visit (30+ min) | 66 | $6,351 | $96 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 79 | $6,197 | $76 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 26 | $4,832 | $186 |
| Return visit (30+ min) | 26 | $3,246 | $105 |
| New patient visit (15+ min) | 32 | $2,006 | $63 |
| Telephone medical discussion with physician, 11-20 minutes | 15 | $1,385 | $73 |
| Telephone medical discussion with physician, 5-10 minutes | 14 | $933 | $44 |
| Short return visit | 17 | $722 | $36 |
2019: 10 services
| Short return visit (20+ min) | 129 | $14,326 | $63 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 55 | $12,606 | $225 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 49 | $10,624 | $66 |
| Biopsy of large bowel using a flexible endoscope | 88 | $7,752 | $87 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 86 | $7,193 | $79 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 36 | $7,111 | $182 |
| New patient visit (30+ min) | 74 | $6,910 | $93 |
| New patient visit (15+ min) | 44 | $2,586 | $59 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 17 | $2,091 | $123 |
| Short return visit | 38 | $1,637 | $38 |
2018: 14 services
| Return visit (30+ min) | 121 | $24,596 | $91 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 55 | $10,931 | $65 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 33 | $7,494 | $227 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 39 | $7,021 | $180 |
| New patient visit (30+ min) | 63 | $5,768 | $92 |
| Biopsy of large bowel using a flexible endoscope | 52 | $4,803 | $92 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 47 | $3,974 | $85 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 15 | $3,479 | $232 |
| Biopsy of large bowel using a flexible endoscope | 28 | $2,906 | $104 |
| Short return visit (20+ min) | 38 | $2,873 | $68 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 25 | $1,969 | $76 |
| New patient visit (15+ min) | 28 | $1,862 | $67 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 15 | $1,814 | $121 |
| Short return visit | 18 | $797 | $40 |
2017: 9 services
| Return visit (30+ min) | 130 | $25,532 | $93 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 79 | $16,082 | $63 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 57 | $10,801 | $177 |
| Biopsy of large bowel using a flexible endoscope | 65 | $7,017 | $108 |
| New patient visit (30+ min) | 70 | $6,743 | $96 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 28 | $6,399 | $229 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 49 | $4,286 | $86 |
| Short return visit (20+ min) | 27 | $1,901 | $63 |
| Short return visit | 12 | $448 | $37 |
2016: 9 services
| Return visit (30+ min) | 117 | $26,106 | $89 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 89 | $19,468 | $62 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 80 | $15,203 | $173 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 28 | $6,898 | $230 |
| Biopsy of large bowel using a flexible endoscope | 51 | $5,004 | $91 |
| New patient visit (30+ min) | 54 | $4,542 | $84 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 43 | $4,240 | $88 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 27 | $2,910 | $104 |
| Short return visit (20+ min) | 29 | $1,965 | $61 |
2015: 9 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 110 | $26,036 | $62 |
| Return visit (30+ min) | 127 | $24,732 | $89 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 80 | $15,938 | $173 |
| Biopsy of large bowel using a flexible endoscope | 59 | $8,400 | $135 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 32 | $8,347 | $261 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 70 | $7,401 | $95 |
| New patient visit (30+ min) | 37 | $3,287 | $89 |
| Short return visit (20+ min) | 28 | $1,945 | $63 |
| Short return visit | 14 | $560 | $33 |
2014: 9 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 115 | $24,632 | $62 |
| Return visit (30+ min) | 122 | $23,316 | $91 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 85 | $15,741 | $171 |
| Biopsy of large bowel using a flexible endoscope | 53 | $7,395 | $134 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 27 | $7,391 | $264 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 64 | $6,020 | $94 |
| New patient visit (45+ min) | 33 | $4,640 | $141 |
| New patient visit (30+ min) | 24 | $1,903 | $79 |
| Short return visit (20+ min) | 23 | $1,348 | $52 |
2013: 9 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 135 | $23,895 | $60 |
| Return visit (30+ min) | 104 | $21,741 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 87 | $15,662 | $168 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 32 | $8,661 | $262 |
| Biopsy of large bowel using a flexible endoscope | 61 | $8,447 | $130 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 70 | $7,532 | $106 |
| New patient visit (30+ min) | 39 | $3,215 | $82 |
| Short return visit (20+ min) | 19 | $1,567 | $65 |
| New patient visit (15+ min) | 11 | $631 | $57 |
Drugs they prescribed that Part D paid
$138,206
Pharmacies billed $138,206 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,035) in 2024. At or below the middle of the specialty; the typical gastroenterology clinician is at 0%.
861 generic and 174 brand-name prescriptions · $138,206 in drug cost · 27 antibiotic prescriptions to 17 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Linzess | 66 | $49,004 | $742 |
| Creon | 12 | $14,262 | $1,189 |
| Dexlansoprazole Dr | 34 | $10,358 | $305 |
| Mesalamine | 15 | $8,068 | $538 |
| Sucralfate | 154 | $6,063 | $39 |
See all 14 drugs
| Linzess | 66 | $49,004 | $742 |
| Creon | 12 | $14,262 | $1,189 |
| Dexlansoprazole Dr | 34 | $10,358 | $305 |
| Mesalamine | 15 | $8,068 | $538 |
| Sucralfate | 154 | $6,063 | $39 |
| Sod Sulf-Potass Sulf-Mag Sulf | 71 | $4,769 | $67 |
| Colesevelam | 19 | $3,569 | $188 |
| Pantoprazole | 222 | $2,646 | $12 |
| Omeprazole | 113 | $2,189 | $19 |
| Famotidine | 98 | $1,154 | $12 |
| Esomeprazole Magnesium | 27 | $641 | $24 |
| Gavilyte-G | 45 | $634 | $14 |
| Peg-3350 and Electrolytes | 25 | $349 | $14 |
| Ondansetron Odt | 17 | $202 | $12 |
Year by year
| 2024 | 1,035 | 344 | 0% (0) | 17% | $138,206 |
| 2023 | 932 | 285 | 0% (0) | 16% | $140,292 |
| 2022 | 981 | 249 | 0% (0) | 29% | $186,705 |
| 2021 | 1,031 | 266 | 0% (0) | 31% | $177,778 |
| 2020 | 940 | 218 | 0% (0) | 26% | $133,483 |
| 2019 | 866 | 234 | 0% (0) | 28% | $122,092 |
| 2018 | 851 | 219 | 0% (0) | 30% | $118,227 |
| 2017 | 755 | 170 | 0% (0) | 25% | $84,807 |
| 2016 | 742 | 164 | 0% (0) | None | $149,490 |
| 2015 | 807 | 156 | 0% (0) | 44% | $146,815 |
| 2014 | 589 | 127 | None | 39% | $73,642 |
| 2013 | 579 | 111 | None | 39% | $61,151 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 13 drugs
| Linzess | 50 | $48,953 | $979 |
| Dexlansoprazole Dr | 47 | $18,341 | $390 |
| Sucralfate | 137 | $10,774 | $79 |
| Sod Sulf-Potass Sulf-Mag Sulf | 51 | $3,968 | $78 |
| Pantoprazole | 184 | $3,636 | $20 |
| Colesevelam | 16 | $3,182 | $199 |
| Colestipol | 12 | $2,608 | $217 |
| Sutab | 13 | $2,190 | $168 |
| Famotidine | 133 | $1,635 | $12 |
| Omeprazole | 92 | $1,249 | $14 |
| Esomeprazole Magnesium | 23 | $1,226 | $53 |
| Rabeprazole | 28 | $959 | $34 |
| Gavilyte-G | 40 | $706 | $18 |
2022: 17 drugs
| Linzess | 81 | $52,874 | $653 |
| Creon | 14 | $28,694 | $2,050 |
| Dexilant | 43 | $22,937 | $533 |
| Dexlansoprazole Dr | 23 | $10,154 | $441 |
| Sucralfate | 145 | $9,931 | $68 |
| Mesalamine | 13 | $6,031 | $464 |
| Suprep | 47 | $5,438 | $116 |
| Colesevelam | 16 | $3,996 | $250 |
| Pantoprazole | 206 | $3,986 | $19 |
| Misoprostol | 21 | $1,681 | $80 |
| Omeprazole | 100 | $1,526 | $15 |
| Famotidine | 83 | $1,474 | $18 |
| Esomeprazole Magnesium | 21 | $1,044 | $50 |
| Dicyclomine | 23 | $859 | $37 |
| Rabeprazole | 14 | $726 | $52 |
| Prevalite | 12 | $480 | $40 |
| Gavilyte-G | 13 | $163 | $13 |
2021: 15 drugs
| Linzess | 67 | $42,097 | $628 |
| Dexilant | 68 | $33,388 | $491 |
| Mesalamine | 15 | $16,465 | $1,098 |
| Sucralfate | 132 | $12,124 | $92 |
| Suprep | 65 | $7,190 | $111 |
| Pantoprazole | 240 | $4,233 | $18 |
| Colestipol | 14 | $3,904 | $279 |
| Colesevelam | 15 | $3,868 | $258 |
| Omeprazole | 117 | $1,928 | $16 |
| Esomeprazole Magnesium | 20 | $1,505 | $75 |
| Famotidine | 92 | $1,350 | $15 |
| Dicyclomine | 29 | $1,249 | $43 |
| Misoprostol | 15 | $1,177 | $78 |
| Rabeprazole | 11 | $286 | $26 |
| Peg-3350 and Electrolytes | 11 | $154 | $14 |
2020: 16 drugs
| Dexilant | 65 | $27,193 | $418 |
| Mesalamine | 18 | $16,772 | $932 |
| Linzess | 25 | $14,244 | $570 |
| Sucralfate | 108 | $8,349 | $77 |
| Colesevelam | 35 | $8,081 | $231 |
| Suprep | 58 | $6,030 | $104 |
| Pantoprazole | 254 | $3,763 | $15 |
| Esomeprazole Magnesium | 24 | $1,894 | $79 |
| Colestipol | 13 | $1,801 | $139 |
| Plenvu | 11 | $1,315 | $120 |
| Misoprostol | 15 | $1,113 | $74 |
| Omeprazole | 104 | $865 | $8 |
| Dicyclomine | 23 | $814 | $35 |
| Famotidine | 49 | $616 | $13 |
| Rabeprazole | 12 | $502 | $42 |
| Gavilyte-G | 14 | $186 | $13 |
2019: 15 drugs
| Dexilant | 62 | $25,192 | $406 |
| Mesalamine | 16 | $18,637 | $1,165 |
| Linzess | 21 | $15,313 | $729 |
| Suprep | 72 | $7,185 | $100 |
| Carafate | 11 | $5,857 | $532 |
| Esomeprazole Magnesium | 17 | $5,761 | $339 |
| Sucralfate | 94 | $4,404 | $47 |
| Colesevelam | 13 | $3,981 | $306 |
| Pantoprazole | 269 | $3,227 | $12 |
| Colestipol | 11 | $1,294 | $118 |
| Omeprazole | 83 | $1,228 | $15 |
| Rabeprazole | 12 | $542 | $45 |
| Famotidine | 35 | $527 | $15 |
| Gavilyte-G | 29 | $368 | $13 |
| Dicyclomine | 25 | $341 | $14 |
2018: 13 drugs
| Dexilant | 59 | $21,767 | $369 |
| Linzess | 33 | $19,615 | $594 |
| Suprep | 93 | $8,722 | $94 |
| Esomeprazole Magnesium | 14 | $5,748 | $411 |
| Sucralfate | 102 | $3,271 | $32 |
| Pantoprazole | 213 | $2,688 | $13 |
| Omeprazole | 69 | $813 | $12 |
| Polyethylene Glycol 3350 | 25 | $800 | $32 |
| Dicyclomine | 37 | $443 | $12 |
| Famotidine | 38 | $357 | $9 |
| Gavilyte-G | 20 | $285 | $14 |
| Ranitidine | 19 | $272 | $14 |
| Ondansetron Odt | 12 | $197 | $16 |
2017: 12 drugs
| Dexilant | 43 | $18,403 | $428 |
| Mesalamine | 12 | $9,010 | $751 |
| Welchol | 20 | $6,854 | $343 |
| Esomeprazole Magnesium | 16 | $5,092 | $318 |
| Suprep | 44 | $3,830 | $87 |
| Pantoprazole | 188 | $3,005 | $16 |
| Sucralfate | 103 | $2,676 | $26 |
| Omeprazole | 64 | $1,558 | $24 |
| Polyethylene Glycol 3350 | 28 | $966 | $35 |
| Dicyclomine | 55 | $363 | $7 |
| Ranitidine | 22 | $360 | $16 |
| Gavilyte-G | 24 | $320 | $13 |
2016: 16 drugs
| Dexilant | 58 | $20,893 | $360 |
| Mesalamine | 12 | $9,072 | $756 |
| Linzess | 22 | $8,271 | $376 |
| Nexium | 18 | $7,499 | $417 |
| Welchol | 14 | $5,556 | $397 |
| Carafate | 12 | $5,079 | $423 |
| Sucralfate | 83 | $2,555 | $31 |
| Suprep | 30 | $2,473 | $82 |
| Pantoprazole | 176 | $2,306 | $13 |
| Omeprazole | 84 | $1,716 | $20 |
| Rabeprazole | 17 | $1,265 | $74 |
| Misoprostol | 12 | $1,100 | $92 |
| Polyethylene Glycol 3350 | 27 | $586 | $22 |
| Gavilyte-G | 18 | $256 | $14 |
| Peg-3350 and Electrolytes | 16 | $198 | $12 |
| Ranitidine | 13 | $51 | $4 |
2015: 17 drugs
| Dexilant | 79 | $21,961 | $278 |
| Canasa | 13 | $18,869 | $1,451 |
| Lialda | 21 | $18,562 | $884 |
| Nexium | 29 | $14,373 | $496 |
| Linzess | 36 | $11,833 | $329 |
| Carafate | 18 | $5,941 | $330 |
| Welchol | 22 | $5,758 | $262 |
| Sucralfate | 69 | $3,141 | $46 |
| Moviprep | 23 | $1,847 | $80 |
| Pantoprazole | 135 | $1,589 | $12 |
| Omeprazole | 97 | $1,547 | $16 |
| Misoprostol | 12 | $1,048 | $87 |
| Polyethylene Glycol 3350 | 39 | $1,034 | $27 |
| Suprep | 11 | $894 | $81 |
| Rabeprazole | 15 | $788 | $53 |
| Peg-3350 and Electrolytes | 20 | $262 | $13 |
| Gavilyte-G | 14 | $195 | $14 |
2014: 12 drugs
| Nexium | 21 | $9,432 | $449 |
| Linzess | 27 | $8,371 | $310 |
| Welchol | 29 | $6,456 | $223 |
| Dexilant | 28 | $6,269 | $224 |
| Polyethylene Glycol 3350 | 48 | $1,912 | $40 |
| Pantoprazole | 84 | $1,572 | $19 |
| Sucralfate | 38 | $1,461 | $38 |
| Rabeprazole | 13 | $954 | $73 |
| Moviprep | 12 | $933 | $78 |
| Omeprazole | 82 | $677 | $8 |
| Peg-3350 and Electrolytes | 22 | $318 | $14 |
| Gavilyte-G | 11 | $162 | $15 |
2013: 12 drugs
| Nexium | 25 | $7,113 | $285 |
| Aciphex | 22 | $7,091 | $322 |
| Dexilant | 26 | $4,843 | $186 |
| Carafate | 12 | $3,434 | $286 |
| Welchol | 20 | $2,943 | $147 |
| Pantoprazole | 100 | $2,081 | $21 |
| Moviprep | 25 | $1,745 | $70 |
| Omeprazole | 122 | $1,730 | $14 |
| Polyethylene Glycol 3350 | 44 | $1,680 | $38 |
| Sucralfate | 20 | $715 | $36 |
| Peg-3350 and Electrolytes | 20 | $317 | $16 |
| Metoclopramide | 15 | $152 | $10 |
Professional record
- NPI
- 1699919100
- Licence
- CA A106864California A106864: Current · expires 2026-10-31
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RG0100X (207RG0100X)
- Mailing address
- 5575 W Las Positas Blvd Ste 130, Pleasanton, CA, 94588
- NPI first listed
- 2009-04-28
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 5725 W Las Positas Blvd Ste 130, Pleasanton, CA, 94588